beat guidanc cut
due covid fx
ep con driven keytruda
anim health rel est revenue ep
management lower revenue ep due
covid pressur neg fx recal issu
faq march flag risk busi prospect
top-lin bottom-lin revenu con
oper incom con
ep con
ep upsid vs model includ revenu cog sg
growth nutshel rev gross profit oper inc pre-tax net
revenu beat rel estim
keytruda
anim
bridion sugammadex
gardasil hpv vaccin
isentress
azn oncolog allianc revenu lynparza
remicad renflexi
revenu miss rel estim
proquad m-m-r ii varivax
januvia franchis steglatro
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
zepati hcv
eisai allianc revenu lenvima
revenu guidanc lower ep cut
revenu guidanc prev midpoint
con
ep guidanc prev midpoint
con guidanc reflect
assum impact assum neg fx impact
chemo phase nsclc os virtual may posit top-lin
ph nsclc detail result follow top-lin
virtual may
keytruda tigit phase data roch tecentriq
tiragolumab tigit combo virtual may
potenti disclosur virtual may
act financi advisor merck co merck connect
intent spin-off product women legaci brand
biosimilar franchis new yet-to-be-nam independ publicly-trad
compani announc februari transact subject market
certain condit merck agre pay fee
financi servic includ fee conting upon consumm
transact pleas refer note end report
per share equat approxim pre-tax
proquad m-m-r ii varivax
per share equat approxim pre-tax
proquad m-m-r ii varivax
valuat methodolog risk
base case remainco ep base case newco ebitda remainco
target multipl peer averag believ justifi given faster
growth prospect balanc slightli greater keytruda concentr newco
women health legaci brand biosimilar target multipl reflect modest growth
potenti estimate debt newco need subtract ev calcul
risk upsid
financi result expect keytruda adjuv trial succeed earli pipelin
surpris competitor shortfal value-enhanc
risk downsid
posit surpris fda disappoint litig regulatori risk covid-driven
suppli trial disrupt
